View in EDS

The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes.

Saved in:
Bibliographic Details
Title: The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes.
Authors: Reader CS; invoX Pharma., Liao W; F-star Therapeutics, Cambridge, UK., Potter-Landua BJ; invoX Pharma., Veyssier CS; invoX Pharma., Seal CJ; invoX Pharma., Brewis N; F-star Therapeutics, Cambridge, UK., Morrow M; invoX Pharma.
Source: Anti-cancer drugs [Anticancer Drugs] 2025 Jul 01; Vol. 36 (6), pp. 447-458. Date of Electronic Publication: 2025 Mar 03.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39960386
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Reader+CS%22">Reader CS</searchLink>; invoX Pharma.<br /><searchLink fieldCode="AU" term="%22Liao+W%22">Liao W</searchLink>; F-star Therapeutics, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Potter-Landua+BJ%22">Potter-Landua BJ</searchLink>; invoX Pharma.<br /><searchLink fieldCode="AU" term="%22Veyssier+CS%22">Veyssier CS</searchLink>; invoX Pharma.<br /><searchLink fieldCode="AU" term="%22Seal+CJ%22">Seal CJ</searchLink>; invoX Pharma.<br /><searchLink fieldCode="AU" term="%22Brewis+N%22">Brewis N</searchLink>; F-star Therapeutics, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Morrow+M%22">Morrow M</searchLink>; invoX Pharma.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229100823%22">Anti-cancer drugs</searchLink> [Anticancer Drugs] 2025 Jul 01; Vol. 36 (6), pp. 447-458. <i>Date of Electronic Publication: </i>2025 Mar 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9100823 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1473-5741 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209594973%22">09594973 </searchLink><i>NLM ISO Abbreviation: </i>Anticancer Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39960386
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1097/CAD.0000000000001705
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 447
    Titles:
      – TitleFull: The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Reader CS
      – PersonEntity:
          Name:
            NameFull: Liao W
      – PersonEntity:
          Name:
            NameFull: Potter-Landua BJ
      – PersonEntity:
          Name:
            NameFull: Veyssier CS
      – PersonEntity:
          Name:
            NameFull: Seal CJ
      – PersonEntity:
          Name:
            NameFull: Brewis N
      – PersonEntity:
          Name:
            NameFull: Morrow M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1473-5741
          Numbering:
            – Type: volume
              Value: 36
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Anti-cancer drugs
              Type: main
ResultId 1